OBJECTIVE： To observe clinical efficacy and safety of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. METHODS： 52 patients with ovarian cancer were randomly divided into control group （22 cases） and observation group （30 cases）. Control group was given paclitaxel， carboplatin， oxaliplatin， doxorubicin and other routine chemotherapy drugs according to disease condition； observation group was additionally given bevacizumab 7.5 mg/kg added into 250 ml 0.9％ Sodium chloride injection， 1 h before chemotherapy， ivgtt， on the basis of control group， and given dexamethasone 10 mg intravenous impulse for pretreatment firstly. A treatment course lasted for 3 weeks， and both groups were given 4-8 courses of treatment. Short-term efficacy， survival time， survival quality and toxic reaction were observed in 2 groups. RESULTS： Short-term total effective rate of observation group was 83.3％， which was significantly higher than 54.5％ of control group， with statistical significance （P＜0.05）； survival time of observation group was （34.0±2.4） months， which was significantly higher than （24.0±3.0） months of control group， with statistical significance （P＜0.05）； survival quality score of observation group was （114.5±2.1）， which was significantly higher than （103.2±2.1） of control group， with statistical significances （P＜0.05）. There was no statistical significance in the incidence of toxic reaction between 2 groups （P＞0.05）. CONCLUSIONS： Bevacizumab combined with chemotherapy shows significant short-term efficacy in the treatment of ovarian cancer， prolongs survival time of patients significantly， and improves survival quality with good safety.